Your cart
Your cart is empty.HEALTH NEWS
Study Title:
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1
Study Abstract
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.
Study Information
JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574. PMID: 37796527; PMCID: PMC10557026.
Full Study
https://pubmed.ncbi.nlm.nih.gov/37796527/Recent News
Behind the Buzz: Alcohol’s Hidden Impact on Gut Health
Quercetin Phytosome & Luteolin: Dynamic Duo for Immune Health and Longevity
Nerve Nutrients for Comfort, Balance, and Neuroprotection
The Power of PEA: Feel Better, Think Sharper, Sleep Deeper
Collagen Peptides and Keratin: Building Blocks for Joints, Bones, and Skin
JUNE SALE
Use code DAILYDETOX thru 6/30